Developing Galectin-3-Targeted Therapeutics in Diseases: Three Distinct Galectin-3 Segments for Targeting
Expert Reviews in Molecular Medicine · 2026 · 28
DOI: 10.1017/erm.2026.10060 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Reviews in Molecular Medicine, online erschienen am 15.06.2026. Verfasst von Paulina Sindrewicz-Goral und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Cell and Systems Biology, https://ror.org/04xs57h96University of Liverpool, UK. Hauptthemen laut MEDLINE: Galectin 3, Neoplasms. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.
Abstract (Originalsprache)
The β -galactoside-binding protein galectin-3 is currently a hotly pursued therapeutic target in cancer, inflammation and fibrosis-associated diseases due to its multi-mode actions and broad impact on the pathogenesis and progress of the diseases. Various natures of galectin-3 inhibitors have been developed and investigated, and several have shown promising results in early-phase clinical trials. All these galectin-3 antagonists were designed to target the canonical carbohydrate-binding site, the S-face, of the galectin-3 carbohydrate recognition domain (CRD). This review discussed the current galectin-3 antagonists and explored their modes of actions, focusing particularly on their targeting regions on galectin-3. It discussed the tri-modular structure of galectin-3 and the roles of different segments in galectin-3 actions. It proposed that, in addition to the canonical carbohydrate-binding sites on the S-face, the non-canonical carbohydrate-binding interface, the F-face of the galectin-3 CRD as well as its flexible N-terminal domain are also targetable in the design of galectin-3-targeted therapeutics. Given the high degree of structural similarities of CRDs among galectin family members but unique nature of galectin-3 N-terminus, antagonists developed against the N-terminal domain of galectin-3 can potentially offer greater target specificity by avoiding cross-reactivity with other galectin members. Antagonists that can interact with more than one segment of galectin-3, or a combination of antagonists against different galectin-3 segments, may potentially provide improved efficacy and therapeutic effectiveness for treatment of galectin-3-mediated pathologies and diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Cell and Systems Biology, https://ror.org/04xs57h96University of Liverpool, UK.
- https://ror.org/02h67vt10Aintree University Hospitals NHS Foundation Trust, Liverpool, UK.
ORCID-Profile: Paulina Sindrewicz-Goral, Oluwatobi Adegbite, Jessie Y Yu, Lu-Gang Yu
Förderung
- Medical Research Council
Zitieren
APA
Sindrewicz-Goral, P., Adegbite, O., Yu, J. Y., & Yu, L. G. (2026). Developing Galectin-3-Targeted Therapeutics in Diseases: Three Distinct Galectin-3 Segments for Targeting. Expert Reviews in Molecular Medicine, 28. https://doi.org/10.1017/erm.2026.10060
Vancouver
Sindrewicz-Goral P, Adegbite O, Yu JY, Yu LG. Developing Galectin-3-Targeted Therapeutics in Diseases: Three Distinct Galectin-3 Segments for Targeting. Expert Reviews in Molecular Medicine. 2026;28. doi:10.1017/erm.2026.10060
BibTeX
@article{SindrewiczGoral2026,
author = {Sindrewicz-Goral, Paulina and Adegbite, Oluwatobi and Yu, Jessie Y and Yu, Lu-Gang},
title = {Developing Galectin-3-Targeted Therapeutics in Diseases: Three Distinct Galectin-3 Segments for Targeting},
journal = {Expert Reviews in Molecular Medicine},
year = {2026},
volume = {28},
doi = {10.1017/erm.2026.10060}
}
EUVIMED